BeiGene Ltd.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2010-01-01

Employees: 10K

Market Cap: $22.1B

Website: http://www.beigene.com

Clinical Trials

A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma

Phase 1

Completed

Conditions: B-cell Lymphoma

Interventions: Drug: Zanubrutinib

First Posted Date: 2017-06-16

Last Posted Date: 2021-10-22

Lead Sponsor: BeiGene

Target Recruit Count: 44

Registration Number: NCT03189524

Locations: 🇨🇳
Tianjin Hematonosis Hospital, Tianjin, Tianjin, China
🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

and more 1 locations

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Locally Advanced or Metastatic Solid Tumors

Interventions: Drug: Pamiparib
Drug: Temozolomide

First Posted Date: 2017-05-12

Last Posted Date: 2024-12-20

Lead Sponsor: BeiGene

Target Recruit Count: 139

Registration Number: NCT03150810

Locations: 🇺🇸
Start Midwest, Grand Rapids, Michigan, United States
🇺🇸
Washington University in St Louis, Saint Louis, Missouri, United States
🇺🇸
Montefiore Medical Park At Eastchester Einstein Campus, Bronx, New York, United States

and more 19 locations

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

Phase 2

Completed

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Zanubrutinib

First Posted Date: 2017-05-09

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 41

Registration Number: NCT03145064

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

and more 8 locations

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

Phase 3

Completed

Conditions: Waldenström's Macroglobulinemia

Interventions: Drug: BGB-3111
Drug: Ibrutinib

First Posted Date: 2017-02-15

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 201

Registration Number: NCT03053440

Locations: 🇺🇸
Mayo Clinic Phoenix, Phoenix, Arizona, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 55 locations

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Phase 1

Completed

Conditions: Lymphoma
Leukemia

Interventions: Drug: Zanubrutinib
Drug: Tislelizumab

First Posted Date: 2016-06-10

Last Posted Date: 2022-07-01

Lead Sponsor: BeiGene

Target Recruit Count: 75

Registration Number: NCT02795182

Locations: 🇦🇺
St Vincent's Hospital, Darlinghurst, New South Wales, Australia
🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

and more 7 locations

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Biological: Tislelizumab
Drug: Pamiparib

First Posted Date: 2016-01-21

Last Posted Date: 2021-12-06

Lead Sponsor: BeiGene

Target Recruit Count: 229

Registration Number: NCT02660034

Locations: 🇦🇺
Prince of Wales, Randwick, New South Wales, Australia
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇬🇧
Sarah Cannon Research Institute, London, United Kingdom

and more 24 locations

Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: BGB-283

First Posted Date: 2015-11-20

Last Posted Date: 2024-10-23

Lead Sponsor: BeiGene

Target Recruit Count: 131

Registration Number: NCT02610361

Locations: 🇦🇺
Chris Obrien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺
Monash Health, Clayton, Victoria, Australia
🇦🇺
Cabrini Hospital Malvern, Malvern, Victoria, Australia

and more 15 locations

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

Phase 1

Completed

Conditions: B-cell Lymphoid Malignancies

Interventions: Drug: Zanubrutinib
Drug: Obinutuzumab

First Posted Date: 2015-10-06

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 119

Registration Number: NCT02569476

Locations: 🇺🇸
Florida Cancer Specialists Fort Myers, Fort Myers, Florida, United States
🇺🇸
Florida Cancer Specialists East, West Palm Beach, Florida, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 11 locations

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Biological: BGB-A317

First Posted Date: 2015-04-03

Last Posted Date: 2021-11-17

Lead Sponsor: BeiGene

Target Recruit Count: 451

Registration Number: NCT02407990

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇦🇺
Austin Health Hospital, Heidelberg, Victoria, Australia
🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia

and more 24 locations

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

Phase 1

Completed

Conditions: For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment

Interventions: Drug: BGB-290

First Posted Date: 2015-02-12

Last Posted Date: 2024-10-23

Lead Sponsor: BeiGene

Target Recruit Count: 101

Registration Number: NCT02361723

Locations: 🇦🇺
Austin Health, Heidelberg, Victoria, Australia
🇦🇺
Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺
Gosford Hospital, Gosford, New South Wales, Australia

and more 3 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy